Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release

International Journal of Pharmaceutics

Volumn 383, Issue 1-2, 2010, Pages 209-215

  Kim, Jin Ki ^a   Park, Jeong Sook ^b   Kim, Chong Kook ^a,c  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Binary mixture; Controlled release; Itraconazole; Lipid nanoparticles

Indexed keywords

ITRACONAZOLE; LIQUID LIPID NANOPARTICLE; MACROGOL 2000; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; TRIOLEIN; TRISTEARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRESSURE; PRIORITY JOURNAL; RAT; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; INFUSIONS, PARENTERAL; ITRACONAZOLE; LIPIDS; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70449526194     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.09.008     Document Type: Article

References (33)

1. Akkar A., and Müller R.H. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur. J. Pharm. Biopharm. 56 (2003) 29-36
2. Beule K.D., and Gestel J.V. Pharmacology of itraconazole. Drugs 61 (2001) 27-37
3. Boogaerts M.A., Maertens J., Van der Geest R., Bosly A., Michaux J.-L., Van Hoof A., Cleeren M., Wostenborghs R., and De Beule K. Pharmacokinetics and safety of a 8-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother. 45 (2001) 981-985
4. Chen W., Gu B., Wang H., Pan J., Lu W., and Hou H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int. J. Pharm. 362 (2008) 133-140
5. Constantinides P.P., Chaubal M.V., and Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60 (2008) 757-767
6. Fromtling R.A. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (1987), J.R. Prous Science Publishers, Barcelona, Spain pp. 233-249
7. Groll A.H., Wood L., Roden M., Mickiene D., Chiou C.C., Townley E., Dad L., Piscitelli S.C., and Walsh T.J. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimocrob. Agents Chemother. 46 (2002) 2554-2563
8. Hanafy A., Spahn-Langguth H., Vergnault G., Grenier P., Tubic Grozdanis M., Lenhardt T., and Langguth P. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev. 59 (2007) 419-426
9. Hong J.Y., Kim J.K., Song Y.K., Park J.S., and Kim C.K. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control Release 110 (2006) 332-338
10. Jenning V., Thunemann A.F., and Gohla S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199 (2000) 167-177
11. Jung J.Y., Yoo S.D., Lee S.H., Kim K.H., Yoon D.S., and Lee K.H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 187 (1999) 209-218
12. Kim J.Y., Kim J.K., Park J.S., Byun Y., and Kim C.K. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30 (2009) 5751-5756
13. Koppel D.E. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: the method of cumulants. J. Chem. Phys. 57 (1972) 4814-4816
14. Lee M.K., Lim S.J., and Kim C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28 (2007) 2137-2146
15. Mehnert W., and Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001) 165-196
16. Miyazaki H.M., Kohno S., Miyazaki Y., Mitsutake K., Tomono K., Kaku M., Koga H., and Hara K. Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. 37 (1993) 2762-2765
17. Müller R.H., and Heinemann S. Fat emulsions for parenteral nutrition. I. Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr. 11 (1992) 223-272
18. Müller R.H., Mäder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-177
19. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., and Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91 (2002) 1414-1422
20. Physician's Desk Reference, 59th ed., 2005. Thomson PDR, Montvale, NJ, pp. 1757-1766.
21. Picardi M., Camera A., Luciano L., Ciancia R., and Rotoli B. Intravenous itraconazole for treating invasive pulmonary aspergillosis in neutriopenic patients with acute lymphoblastic leukemia. Haematologica 88 (2003) ELT01
22. Precht D. Fat crystal structure in cream and butter. In: Garti N., and Sato K. (Eds). Crystallization and Polymorphism of Fats and Fatty Acids (1988), Marcel Dekker, New York 305-355
23. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C.S., Wielgos T., White R., Cook C., Barker K., and Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339 (2007) 251-260
24. Schwarz C., Mehnert W., Lucks J.S., and Müller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control Release 30 (1994) 83-96
25. Shin J.H., Choi K.Y., Kim Y.C., and Lee M.G. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob. Agents Chemother. 48 (2004) 1756-1762
26. Siekmann B., and Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1 (1992) 123-126
27. Souto E.B., Wissing S.A., Barbosa C.M., and Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278 (2004) 71-77
28. Stevens P.J., Sekido M., and Lee R.J. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res. 24 (2004) 161-165
29. Venkateswarlu V., and Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control Release 95 (2004) 627-638
30. Verreck G., Six K., Van den Mooter G., Baert L., Peeters J., and Brewster M.E. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int. J. Pharm. 251 (2003) 165-174
31. Westesen K., Bunjes H., and Koch M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control Release 48 (1997) 223-236
32. Yao M., Chen L., and Srinivas N.R. Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. J. Chromatogr. B: Biomed. Sci. Appl. 752 (2001) 9-16
33. Yi Y., Yoon H.J., Kim B.O., Shim M., Kim S.O., Hwang S.J., and Seo M.H. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J. Control Release 117 (2007) 59-67